Review outlines diagnosis and individualized treatment of IgG4-related kidney disease

A Treatment Standard review in Nephrology Dialysis Transplantation presents a nephrology-oriented framework for IgG4-related kidney disease, a manifestation of systemic immune-mediated fibro-inflammatory disease. Renal involvement includes tubulointerstitial nephritis, membranous nephropathy and obstructive uropathy caused by retroperitoneal fibrosis. Diagnosis requires integration of clinical and laboratory findings, imaging and histopathology because no single biomarker has sufficient sensitivity or specificity.

The review identifies glucocorticoids as the cornerstone of induction therapy, typically producing rapid clinical responses. However, relapses and glucocorticoid toxicity support consideration of steroid-sparing approaches. It describes results with conventional immunosuppressive agents as controversial and reports high efficacy with B-cell-targeting therapies, particularly rituximab, in induction and maintenance settings. The available abstract provides no quantitative treatment effects, sample sizes or comparative safety data.

Management should reflect the pattern of renal involvement, organ dysfunction and likelihood of reversibility. Although immunosuppressive treatments overlap, parenchymal kidney disease and retroperitoneal fibrosis differ in injury mechanisms, treatment goals and monitoring needs. Obstructive uropathy may require interventional procedures alongside immunosuppression. Long-term monitoring is emphasized because of relapse and potential chronic kidney disease. This is a review rather than a new trial; the full text was unavailable for assessment of supporting evidence.